ENDRA CEO Michelon resigns; board member Tokman named acting CEO, new CFO and regulatory head appointed

ENDRA Life Sciences Inc.

Francois Michelon stepped down as CEO and board member effective Aug 12, 2024; separation includes 4 months' salary and 12 months' healthcare coverage.
Alexander Tokman, board member since 2008, appointed acting CEO and Chairman effective Aug 13, 2024; Tokman has 24+ years of commercial leadership and prior GE Healthcare executive experience.
Ziad Rouag appointed Head of Regulatory and Clinical Affairs; Richard Jacroux appointed CFO; Irina Pestrikova to transition and remain advisor.
Tokman will focus on regulatory approval and commercial launch of TAEUS system with strict fiscal discipline.
No disagreement involved in Michelon's resignation; separation agreement includes release of claims and termination of restrictive covenants.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Francois Michelon

Chief Executive Officer and Director

NDRA · ENDRA Life Sciences Inc.

Effective: 2024-08-12
Successor: Alexander Tokman
Filed: August 13, 2024, 7:59 PM ET

Francois Michelon Resignation On August 12, 2024, ENDRA Life Sciences Inc. (“ENDRA” or the “Company”) and Francois Michelon mutually agreed on Mr. Michelon’s resignation as the Company’s Chief Executive Officer and as a member of the Company’s Board of Directors (the “Board”), effective August 12, 2024.

Appointed (interim)

Alexander Tokman

Acting Chief Executive Officer and Chairman

NDRA · ENDRA Life Sciences Inc.

Effective: 2024-08-13
Filed: August 13, 2024, 7:59 PM ET

Appointment of Alexander Tokman as Acting Chief Executive Officer Effective August 13, 2024, the Board appointed Alexander Tokman as the Company’s acting Chief Executive Officer and Chairman.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Francois Michelon resigned as Chief Executive Officer and Director at ENDRA Life Sciences Inc..

Action: resigned
Role: Chief Executive Officer and Director

Exact text from the filing

Francois Michelon Resignation On August 12, 2024, ENDRA Life Sciences Inc. (“ENDRA” or the “Company”) and Francois Michelon mutually agreed on Mr. Michelon’s resignation as the Company’s Chief Executive Officer and as a member of the Company’s Board of Directors (the “Board”), effective August 12, 2024.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Alexander Tokman was appointed as Acting Chief Executive Officer and Chairman at ENDRA Life Sciences Inc..

Action: appointed
Role: Acting Chief Executive Officer and Chairman

Exact text from the filing

Appointment of Alexander Tokman as Acting Chief Executive Officer Effective August 13, 2024, the Board appointed Alexander Tokman as the Company’s acting Chief Executive Officer and Chairman.

View on SEC.gov

ENDRA Life Sciences Inc. filing history →

Source: SEC EDGAR

accession 0001654954-24-010399

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.